Engineered Bacillus subtilis as oral probiotics to enhance clearance of blood lactate.

Autor:	Yang M; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States., Hutchinson N; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, United States., Ye N; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, United States., Yin J; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States., Guan M; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States., Wang Z; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, United States., Chen P; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, 02115, United States., Yang S; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States., Crane JD; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA 02139., Zhang K; Department of Bioengineering, Northeastern University, Boston, MA, 02115, United States.; Department of Chemistry and Chemical Biology, Northeastern University, Boston, MA, 02115, United States., He X; Department of Microbiology, The Forsyth Institute, Cambridge, MA, 02142, United States.; Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, 02115, United States., Li J; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, United States.
Jazyk:	angličtina
Zdroj:	BioRxiv : the preprint server for biology [bioRxiv] 2024 May 12. Date of Electronic Publication: 2024 May 12.
DOI:	10.1101/2023.11.30.569300
Abstrakt:	Elevated lactate concentrations are implicated in various acute and chronic diseases such as sepsis and mitochondrial dysfunction, respectively. Conversely, ineffective lactate clearance is associated with poor clinical prognoses and high mortality in these diseases. While several groups have proposed using small molecule inhibitors and enzyme replacement to reduce circulating lactate, there are few practical and effective ways to manage this condition. Recent evidence suggests that lactate is exchanged between systemic circulation and the gut, allowing bidirectional modulation between the gut microbiota and peripheral tissues. Inspired by these findings, this work seeks to engineer spore-forming probiotic B. subtilis strains to enable intestinal delivery of lactate oxidase as a therapeutic enzyme. After strain optimization, we showed that oral administration of engineered B. subtilis spores to the gut of mice reduced elevations in blood lactate in two different mouse models involving exogenous challenge or pharmacologic perturbation without disrupting gut microbiota composition, liver function, or immune homeostasis. Taken together, through the oral delivery of engineered probiotic spores to the gastrointestinal tract, our proof-of-concept study offers a practical strategy to aid in the management of disease states with elevated blood lactate and provides a new approach to 'knocking down' circulating metabolites to help understand their roles in host physiological and pathological processes. Competing Interests: A provisional patent has been filed by the University of Michigan.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu